Q-omics provides the consensus-scored USP44 profile across patient tissues and cancer cell-line models. USP44 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, USP44 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, USP44 RNA expression shows 18,388 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where USP44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP44 survival associations across molecular data types. USP44 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP44 RNA expression–survival associations across cancer types. High USP44 expression shows unfavorable associations in ACC, SCLC and MESO, but favorable associations in HNSC, UCS and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for USP44 RNA expression.
This table summarizes USP44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP44 shows lower tumor expression in KIRC, LUAD, KICH, THCA, LUSC and COAD. The KIRC box plot shows higher USP44 RNA expression in normal versus tumor tissue (log2 FC = −1.346, t-test p < 0.001).
This table shows molecular features associated with USP44 in patient tissues and cancer cell lines. In patient samples, USP44 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
